WASHINGTON, DC, Oct. 3 – Psychiatric Genomics anticipates closing a Series B round of financing worth between $20 million and $25 million later in the current quarter, the company’s president and CSO told GenomeWeb on Wednesday. 

Michael Palfreyman, who is also Psychiatric Genomics’ founder, could not say what fund will be leading the round, but said that Oxford Bioscience, which led the company’s Series A round, will be a participant.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

In Science this week: in vitro generation of human reproductive cells, and more.